Categories: Wire Stories

Ochre Bio Announces Participation in Upcoming Conferences

OXFORD, England–(BUSINESS WIRE)–#chronicOchre Bio, an innovator in chronic liver disease drug development, today announced its participation in upcoming investor and industry conferences.

WebSummit
Presentation Title: Why you should love your liver

Date/Time: Nov 4, 1:36 WET – 1:47 pm Western European Time

Location: The Altice Arena and FIL, Rossio dos Olivais, 1990-231 Lisbon, Portugal

Presenter: Jack O�Meara, CEO & Co-Founder, Ochre Bio

Big Data and AI Innovation in Drug Discovery

Artificial Intelligence (AI) and big data approaches in drug discovery have gained substantial momentum over the past few years, with the benefit of speeding up drug development timelines as well as reducing research costs. Ochre Bio employs genomics-led target discovery and human-based preclinical models and RNA medicine to develop new therapies for chronic liver diseases. Seeing the infinite potential of AI and big data’s involvement in drug development, Ochre Bio will hold a symposium in Taipei, Taiwan on this trending topic.

Date/Time: Wednesday, Nov. 9, 9:30-12:15 pm

Location: 2nd Floor, Building C, National Biotechnology Research Park , No. 99, Lane 130, Section 1, Institute Road, Nangang District, Taipei, Taiwan

Symposia Information: https://geneonline.news/ochre-bio-ai-big-data-symposium/
Agenda and registration: https://forms.gle/gQeiQaPbexY7ACqy9

Speakers include industry leaders in the field of big data, genomics and drug development:

  • Dr. Quin Wills, CSO of Ochre Bio
  • Dr. Jimmy Lin, CEO of Insilico Medicine Taiwan
  • Dr. Inca Chen, RD Manager of Acer
  • Prof Liao, CEO of Syncell

LSX Inv€$tival Showcase
Date: Monday, Nov. 14, 10:45 am – 11:00 am UK time

Location: 1 Old Billingsgate Walk, London, UK

Presenter: Jack O’Meara, CEO & Co-Founder, Ochre Bio

Jefferies London Healthcare Conference

Date: November 15-17, 2022

Location: Waldorf Hilton (Aldwych), London, UK

To meet with the Ochre Bio team at these events, contact@ochre-bio.com.

About Ochre Bio

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com. Follow us on Twitter @OchreBio.

Contacts

Media

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

Alex

Recent Posts

SEAX Global Acquires Major Stake in Interlink Telecom to Accelerate ASEAN Expansion

Acquisition creates a fully integrated regional connectivity platform, enabling seamless, low-latency connectivity that supports ASEAN’s…

2 days ago

M7 World Championship unveils first Opening Ceremony, tournament draw, and M7 Pass—elevates Indonesia on global stage

The Swiss Stage sets up early mouthwatering clashes between tournament favourites—Team Liquid face Aurora Gaming…

2 days ago

A First in the Asia-Pacific – Taiwan Leads the Launch of the Early Kidney Disease Annual Report, Opening a New Era in Advancing Kidney Care

TAIPEI, TAIWAN - Media OutReach Newswire - 11 December 2025 - Taiwan's chronic disease care…

2 days ago

The Government of Angola Launches an International Public Tender for the Management of the Namibe Corridor

LUANDA, ANGOLA - EQS Newswire - 12 December 2025 - The Ministry of Transport of…

2 days ago

VinFast VF 8 – Crafted for high-expectation markets in the GCC

Premium design meets industry-leading warranty and long-term supportDUBAI, UAE - Media OutReach Newswire - 12…

2 days ago

The 7th Hainan Island International Film Festival Concludes Successfully, With ‘Black Rabbit, White Rabbit’ Receiving the Top Honor

SANYA, CHINA - Media OutReach Newswire - 12 December 2025 - The 7th Hainan Island…

2 days ago